Usefulness of compounds with monacolin K in a case of statins intolerance

  1. Parra-Virto, Alejandro
  2. Torres do Rego, Ana
  3. Demelo-Rodríguez, Pablo
  4. Millán Núñez-Cortés, Jesús
  5. Álvarez-Sala, Luis A.
Revista:
Clínica e investigación en arteriosclerosis

ISSN: 0214-9168 1578-1879

Año de publicación: 2018

Volumen: 30

Número: 6

Páginas: 268-270

Tipo: Artículo

DOI: 10.1016/J.ARTERI.2018.06.003 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Clínica e investigación en arteriosclerosis

Resumen

Many patients with familial hypercholesterolaemia (FH) or in secondary prevention situations and with statin intolerance do not achieve LDL-C targets, and require treatment with PCSK9 inhibitors (iPCSK9) and ezetimibe. The case is presented on a patient with FH and total intolerance to statins. Treatment with iPCSK9 and ezetimibe failed to achieve her LDL-C target. A compound with red yeast rice derivatives containing 3 mg of monacolin K was added, with good therapeutic compliance, and a very good control of LDL-C. The addition of red yeast rice derivatives containing low doses of monacolin K, together with IPCSK9 in patients with total intolerance to statins, may open a new path to obtain LDL-C targets in patients with high/very high cardiovascular risk.